Scandinavian Biolabs (SBL), a Danish innovator within the haircare trade, introduced the closing of a €4 million funding spherical led by Auréa Group marking a major milestone alongside the corporate’s progress journey. Auréa joins present traders Blazar Capital on the board of SBL.
Based in 2020, Scandinavian Biolabs has established itself as a frontrunner in science-backed, non-invasive, preventative merchandise focusing on early-stage hair loss. The corporate’s flagship product, the Bio-Pilixin® Activation Serum, has been a game-changer available in the market, and has been clinically examined for its optimistic results.
Scandinavian Biolabs initially launched as a direct-to-consumer (DTC) model, quickly constructing a loyal buyer base via its on-line platform. Constructing on this success, the model has expanded into retail, and numerous pharmacies throughout a number of geographies.
Anders Reckendorff, CEO and Co-Founding father of Scandinavian Biolabs, mentioned: “We’ve constructed a powerful basis with our progressive merchandise and confirmed that if we will present our clients worth and outcomes, we will even have a powerful enterprise. We’re excited to be joined by our new traders who may also help us leapfrog our progress via their expertise and know-how.”
With over 140,000 clients supported to this point, and a Trustpilot rating of 4.5 out of 5, Scandinavian Biolabs is on a quick monitor to change into the popular resolution for dependable, examined and trustworthy hair-care merchandise that work along with your physique. SevenVentures (A part of Professional. SiebenSat.1 Group) is supporting the German enlargement via a strategic TV collaboration.
The €4 million money infusion from Auréa will allow Scandinavian Biolabs to pursue its formidable progress plans extra aggressively forging a management place within the UK, Germany, and the Nordics, whereas additionally coming into the US market, scaling the enterprise via a web based providing, and increasing strategic retail corresponding to pharmacies.
Auréa Fund commented: “Auréa is delighted to have been chosen by the Scandinavian Biolabs as their most popular investor for the expertise and operational value-add that we deliver along with the expansion capital. We imagine within the founders and the actually differentiated and efficacious merchandise that they’ve developed. We’re assured that collectively we’ll scale this into a major worldwide model.”
